TW202108624A - 投予抗cd38抗體的方法 - Google Patents

投予抗cd38抗體的方法 Download PDF

Info

Publication number
TW202108624A
TW202108624A TW109116104A TW109116104A TW202108624A TW 202108624 A TW202108624 A TW 202108624A TW 109116104 A TW109116104 A TW 109116104A TW 109116104 A TW109116104 A TW 109116104A TW 202108624 A TW202108624 A TW 202108624A
Authority
TW
Taiwan
Prior art keywords
antibody
infusion
administered
hour
individual
Prior art date
Application number
TW109116104A
Other languages
English (en)
Chinese (zh)
Inventor
赫洛伊斯 奧黛特
席維亞 瑪莉恩
桑布拉諾 法蘭克 坎帕納
Original Assignee
法商賽諾菲公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商賽諾菲公司 filed Critical 法商賽諾菲公司
Publication of TW202108624A publication Critical patent/TW202108624A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW109116104A 2019-05-14 2020-05-14 投予抗cd38抗體的方法 TW202108624A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962847825P 2019-05-14 2019-05-14
US62/847,825 2019-05-14
US201962860739P 2019-06-12 2019-06-12
US62/860,739 2019-06-12
US201962899088P 2019-09-11 2019-09-11
US62/899,088 2019-09-11
EP20305223.8 2020-03-03
EP20305223 2020-03-03

Publications (1)

Publication Number Publication Date
TW202108624A true TW202108624A (zh) 2021-03-01

Family

ID=71094805

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109116104A TW202108624A (zh) 2019-05-14 2020-05-14 投予抗cd38抗體的方法

Country Status (15)

Country Link
US (1) US20210171650A1 (cg-RX-API-DMAC7.html)
EP (1) EP3969004A1 (cg-RX-API-DMAC7.html)
JP (2) JP7801132B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220008305A (cg-RX-API-DMAC7.html)
CN (2) CN120501855A (cg-RX-API-DMAC7.html)
AU (1) AU2020274169A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022503A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140034A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021016606A2 (cg-RX-API-DMAC7.html)
IL (1) IL287832A (cg-RX-API-DMAC7.html)
MA (1) MA55967A (cg-RX-API-DMAC7.html)
MX (1) MX2021013910A (cg-RX-API-DMAC7.html)
SG (1) SG11202112513YA (cg-RX-API-DMAC7.html)
TW (1) TW202108624A (cg-RX-API-DMAC7.html)
WO (1) WO2020232173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
WO2020250033A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
IL285110B2 (en) * 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Also Published As

Publication number Publication date
JP7801132B2 (ja) 2026-01-16
WO2020232173A1 (en) 2020-11-19
US20210171650A1 (en) 2021-06-10
EP3969004A1 (en) 2022-03-23
CN120501855A (zh) 2025-08-19
MA55967A (fr) 2022-03-23
CO2021016606A2 (es) 2022-04-29
CA3140034A1 (en) 2020-11-19
AU2020274169A1 (en) 2022-01-20
JP2025166108A (ja) 2025-11-05
SG11202112513YA (en) 2021-12-30
JP2022532356A (ja) 2022-07-14
IL287832A (en) 2022-01-01
CN114080233A (zh) 2022-02-22
BR112021022503A2 (pt) 2021-12-28
MX2021013910A (es) 2022-03-11
KR20220008305A (ko) 2022-01-20

Similar Documents

Publication Publication Date Title
US20240190984A1 (en) Methods of treating multiple myeloma
CN120501855A (zh) 给予抗cd38抗体以治疗多发性骨髓瘤的方法
JP2025061126A (ja) Ror1抗体イムノコンジュゲートによる癌の治療
AU2018314765C1 (en) Obinutuzumab treatment of a DLBCL patient subgroup
CN119947713A (zh) 用于精准癌症治疗的组合物及精准癌症治疗方法
US20250134997A1 (en) Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy in ctdna high risk patients
TW202541838A (zh) 抗cd38抗體在治療新診斷的多發性骨髓瘤中之用途
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
TWI870415B (zh) 使用抗cd38抗體之組合療法
RU2838203C2 (ru) Способы лечения множественной миеломы